Sponsor Overview
Explore verified public information about Poxel's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Poxel is committed to making investigational products available to seriously ill patients who have exhausted other treatment options and unable to participate in a clinical study.”
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Patient Eligibility Criteria: To be eligible for access to an investigational product, a patient must meet the following criteria: In addition to the patient eligibility requirements, the investigational product must meet the following criteria: Treating Physician Criteria and Responsibilities: The physician(s) attending to the patient(s) who is/are receiving an investigational product through expanded use access is (are) properly licensed in the U.S. and fully qualified to administer the product. The physician must agree in writing to comply with: Available Therapies via Single-Patient EA PXL065 for an adult male with a confirmed diagnosis of X-linked adrenoleukodystrophy. Disease/Category-Specific EA Policies/Criteria https://www.poxelpharma.com/en_us/pipeline/clinical-trials/expanded-access-policy
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.